Cappuzzo F, McCleod M, Hussein M, et al. IMpower130: progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. ESMO 2018, abstract LBA53.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker